SG146622A1 - Differentially expressed tumour-specific polypeptides for use in the diagnosis and treatment of cancer - Google Patents
Differentially expressed tumour-specific polypeptides for use in the diagnosis and treatment of cancerInfo
- Publication number
- SG146622A1 SG146622A1 SG200806620-1A SG2008066201A SG146622A1 SG 146622 A1 SG146622 A1 SG 146622A1 SG 2008066201 A SG2008066201 A SG 2008066201A SG 146622 A1 SG146622 A1 SG 146622A1
- Authority
- SG
- Singapore
- Prior art keywords
- protein
- diagnosis
- cancer
- proteins
- treatment
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 7
- 201000011510 cancer Diseases 0.000 title abstract 4
- 238000003745 diagnosis Methods 0.000 title abstract 4
- 238000011282 treatment Methods 0.000 title abstract 3
- 229920001184 polypeptide Polymers 0.000 title abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 5
- 102000004169 proteins and genes Human genes 0.000 abstract 5
- 102100028538 Guanylate-binding protein 4 Human genes 0.000 abstract 2
- 101710110797 Guanylate-binding protein 4 Proteins 0.000 abstract 2
- 101000831927 Homo sapiens Stomatin-like protein 2, mitochondrial Proteins 0.000 abstract 2
- 101000695537 Homo sapiens Synaptophysin-like protein 1 Proteins 0.000 abstract 2
- 102100023350 Integral membrane protein 2B Human genes 0.000 abstract 2
- 101710180845 Integral membrane protein 2B Proteins 0.000 abstract 2
- 102100024172 Stomatin-like protein 2, mitochondrial Human genes 0.000 abstract 2
- 102100028532 Synaptophysin-like protein 1 Human genes 0.000 abstract 2
- 102000008230 Toll-like receptor 3 Human genes 0.000 abstract 2
- 108010060885 Toll-like receptor 3 Proteins 0.000 abstract 2
- 102100032503 Transmembrane 9 superfamily member 2 Human genes 0.000 abstract 2
- 101710127170 Transmembrane 9 superfamily member 2 Proteins 0.000 abstract 2
- 230000004071 biological effect Effects 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 230000014509 gene expression Effects 0.000 abstract 2
- 238000004393 prognosis Methods 0.000 abstract 2
- 102100034452 Alternative prion protein Human genes 0.000 abstract 1
- 102100034613 Annexin A2 Human genes 0.000 abstract 1
- 108090000668 Annexin A2 Proteins 0.000 abstract 1
- 108010062745 Chloride Channels Proteins 0.000 abstract 1
- 102000011045 Chloride Channels Human genes 0.000 abstract 1
- 102000034286 G proteins Human genes 0.000 abstract 1
- 108091006027 G proteins Proteins 0.000 abstract 1
- 101000924727 Homo sapiens Alternative prion protein Proteins 0.000 abstract 1
- 101000573901 Homo sapiens Major prion protein Proteins 0.000 abstract 1
- 102100021918 Low-density lipoprotein receptor-related protein 4 Human genes 0.000 abstract 1
- 101710123602 Low-density lipoprotein receptor-related protein 4 Proteins 0.000 abstract 1
- 102000018697 Membrane Proteins Human genes 0.000 abstract 1
- 108010052285 Membrane Proteins Proteins 0.000 abstract 1
- 101150012056 OPRL1 gene Proteins 0.000 abstract 1
- 102000008937 Zona Pellucida Glycoproteins Human genes 0.000 abstract 1
- 108010074006 Zona Pellucida Glycoproteins Proteins 0.000 abstract 1
- 102100023634 Zona pellucida sperm-binding protein 3 Human genes 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 230000000692 anti-sense effect Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000005516 engineering process Methods 0.000 abstract 1
- 230000001434 glomerular Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 239000002773 nucleotide Substances 0.000 abstract 1
- 125000003729 nucleotide group Chemical group 0.000 abstract 1
- 229940127240 opiate Drugs 0.000 abstract 1
- 239000002157 polynucleotide Substances 0.000 abstract 1
- 102000040430 polynucleotide Human genes 0.000 abstract 1
- 108091033319 polynucleotide Proteins 0.000 abstract 1
- 238000012216 screening Methods 0.000 abstract 1
- 238000007423 screening assay Methods 0.000 abstract 1
- 102000030938 small GTPase Human genes 0.000 abstract 1
- 108060007624 small GTPase Proteins 0.000 abstract 1
- 150000003431 steroids Chemical class 0.000 abstract 1
- 230000008685 targeting Effects 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Analytical Chemistry (AREA)
- Biomedical Technology (AREA)
- Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Urology & Nephrology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Wood Science & Technology (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP03090307 | 2003-09-18 | ||
| US51207803P | 2003-10-20 | 2003-10-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG146622A1 true SG146622A1 (en) | 2008-10-30 |
Family
ID=37657558
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG200806620-1A SG146622A1 (en) | 2003-09-18 | 2004-09-20 | Differentially expressed tumour-specific polypeptides for use in the diagnosis and treatment of cancer |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20090252721A1 (enExample) |
| EP (2) | EP1673470A2 (enExample) |
| JP (1) | JP2007521015A (enExample) |
| CN (1) | CN1902326A (enExample) |
| AU (1) | AU2004272747A1 (enExample) |
| BR (1) | BRPI0414446A (enExample) |
| CA (1) | CA2539490A1 (enExample) |
| IL (1) | IL174047A0 (enExample) |
| SG (1) | SG146622A1 (enExample) |
| WO (1) | WO2005026735A2 (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2599875A1 (en) * | 2005-03-03 | 2006-09-08 | Takeda Pharmaceutical Company Limited | Preventive/therapeutic agent for cancer |
| WO2006127976A2 (en) * | 2005-05-24 | 2006-11-30 | Isis Pharmaceuticals, Inc. | Compositions and their uses directed to ptpru |
| DE602006015508D1 (de) * | 2005-11-16 | 2010-08-26 | Pantarhei Bioscience Bv | Pharmazeutische zusammensetzung zur behandlung oder prävention von ovarialkrebs |
| US20100028335A1 (en) * | 2007-02-02 | 2010-02-04 | Novartis Ag | Compositions and Methods to Treat Bone Related Disorders |
| US20080299138A1 (en) * | 2007-05-25 | 2008-12-04 | Duffy Karen E | Toll-Like Receptor 3 Modulators and Uses Thereof |
| EP2195467B1 (en) * | 2007-09-06 | 2016-12-14 | bioTheranostics, Inc. | Tumor grading and cancer prognosis in breast cancer |
| US8158373B2 (en) * | 2008-03-25 | 2012-04-17 | Case Western Reserve University | Method of detecting cancer and evaluating cancer prognosis |
| WO2010056993A2 (en) * | 2008-11-14 | 2010-05-20 | Emory University | Prostate cancer biomarkers to predict recurrence and metastatic potential |
| WO2010075521A1 (en) * | 2008-12-23 | 2010-07-01 | Case Western Reserve University | Compositions and methods of treating cancer |
| US8940826B2 (en) | 2009-07-16 | 2015-01-27 | Omnova Solutions Inc. | Protective coating compositions |
| MY166040A (en) | 2010-09-15 | 2018-05-21 | Almac Diagnostics Ltd | Molecular diagnostic test for cancer |
| EP2809800A1 (en) | 2012-01-30 | 2014-12-10 | VIB vzw | Means and method for diagnosis and treatment of alzheimer's disease |
| IN2014DN06898A (enExample) * | 2012-03-14 | 2015-05-15 | Salk Inst For Biological Studi | |
| JP6327662B2 (ja) * | 2012-09-26 | 2018-05-23 | 学校法人藤田学園 | 細胞表面タンパクを抗原とする抗体を測定する方法 |
| WO2016080830A2 (en) * | 2014-11-18 | 2016-05-26 | Pantarhei Bioscience B.V. | Immunotherapeutic method for treating pancreatic cancer |
| CN109646685A (zh) * | 2017-10-12 | 2019-04-19 | 北京医院 | stomatin蛋白及其编码基因在肺癌诊断治疗中的应用 |
| CN111394370B (zh) * | 2020-03-03 | 2022-03-25 | 华南农业大学 | 一种猪RagA基因及其应用 |
| JP2023518976A (ja) | 2020-03-23 | 2023-05-09 | エイチディーティー バイオ コーポレーション | Ｒｎａを送達するための組成物および方法 |
| CN114540349B (zh) * | 2020-11-27 | 2024-11-22 | 中国科学院分子细胞科学卓越创新中心 | 结合yb-1蛋白的核酸分子 |
| AU2022351009A1 (en) | 2021-09-22 | 2024-04-11 | Hdt Bio Corp. | Rna vaccines against infectious diseases |
| WO2023048758A1 (en) | 2021-09-22 | 2023-03-30 | Hdt Bio Corp. | Dried nanoparticle compositions |
| KR20240099177A (ko) | 2021-09-22 | 2024-06-28 | 에이치디티 바이오 코포레이션 | SARS-CoV-2 RNA 백신 조성물 및 사용 방법 |
| KR20240111819A (ko) | 2021-09-22 | 2024-07-17 | 에이치디티 바이오 코포레이션 | 암 치료 조성물 및 이들의 용도 |
| CN116482367A (zh) * | 2023-05-04 | 2023-07-25 | 中国中医科学院望京医院(中国中医科学院骨伤科研究所) | 一种联合mSEPT9检测和生物标志物的结直肠癌检测方法 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0003415A3 (en) | 1978-01-20 | 1979-08-22 | Glaxo Group Limited | Beta-lactam compounds, processes for their preparation,compositions containing them and intermediates of use in their preparation |
| US4843000A (en) | 1979-12-26 | 1989-06-27 | Syntex (U.S.A.) Inc. | Simultaneous calibration heterogeneous immunoassay |
| US4849338A (en) | 1982-07-16 | 1989-07-18 | Syntex (U.S.A.) Inc. | Simultaneous calibration heterogeneous immunoassay |
| US4366241A (en) | 1980-08-07 | 1982-12-28 | Syva Company | Concentrating zone method in heterogeneous immunoassays |
| US4520110A (en) | 1981-10-06 | 1985-05-28 | The Board Of Trustees Of The Leland Stanford Junior University | Fluorescent immunoassay employing a phycobiliprotein labeled ligand or receptor |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4542104A (en) | 1983-04-06 | 1985-09-17 | The Board Of Trustees Of The Leland Stanford Jr. Univ. | Phycobiliprotein fluorescent conjugates |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5185444A (en) | 1985-03-15 | 1993-02-09 | Anti-Gene Deveopment Group | Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages |
| US5217866A (en) | 1985-03-15 | 1993-06-08 | Anti-Gene Development Group | Polynucleotide assay reagent and method |
| US4902505A (en) | 1986-07-30 | 1990-02-20 | Alkermes | Chimeric peptides for neuropeptide delivery through the blood-brain barrier |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US4904582A (en) | 1987-06-11 | 1990-02-27 | Synthetic Genetics | Novel amphiphilic nucleic acid conjugates |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| GB9705949D0 (en) | 1997-03-21 | 1997-05-07 | Electrophoretics International | Diagnosis of tumours and other abnormalities of body cells |
| US6197543B1 (en) * | 1997-10-28 | 2001-03-06 | Incyte Pharmaceuticals, Inc. | Human vesicle membrane protein-like proteins |
| US6902898B2 (en) * | 1998-11-16 | 2005-06-07 | National Institute Of Advanced Industrial Science And Technology | Human derived bradeion proteins, DNA coding for the proteins, and uses thereof |
| EP1033404A1 (en) * | 1999-01-29 | 2000-09-06 | F. Hoffmann-La Roche Ag | New gene with down-regulated expression in metastatic human melanoma cells |
| US6228392B1 (en) | 1999-04-29 | 2001-05-08 | Gene Tools, Llc | Osmotic delivery composition, solution, and method |
| CA2384713A1 (en) * | 1999-09-29 | 2001-04-05 | Human Genome Sciences, Inc. | Colon and colon cancer associated polynucleotides and polypeptides |
| US20030104413A1 (en) * | 2000-07-14 | 2003-06-05 | Tang Y. Tom | Novel Nucleic acids and polypeptides |
| US20030108926A1 (en) * | 2000-03-15 | 2003-06-12 | Eos Biotechnology, Inc. | Novel methods of diagnosing colorectal cancer, compositions, and methods of screening for colorectal cancer modulators |
| JP2004512023A (ja) * | 2000-06-09 | 2004-04-22 | コリクサ コーポレイション | 結腸癌の治療および診断のための組成物および方法 |
| AU2001285047A1 (en) * | 2000-08-16 | 2002-02-25 | Chiron Corporation | Human genes and gene expression products |
| US20030134283A1 (en) * | 2000-10-03 | 2003-07-17 | Peterson David P. | Genes regulated in dendritic cell differentiation |
| US20020160382A1 (en) * | 2000-10-11 | 2002-10-31 | Lasek Amy W. | Genes expressed in colon cancer |
| WO2003029273A2 (en) * | 2001-09-28 | 2003-04-10 | Whitehead Institute For Biomedical Research | Classification of lung carcinomas using gene expression analysis |
| EP1308459A3 (en) * | 2001-11-05 | 2003-07-09 | Research Association for Biotechnology | Full-length cDNA sequences |
| AU2003304203A1 (en) * | 2002-10-29 | 2005-01-04 | Pharmacia Corporation | Differentially expressed genes involved in cancer, the polypeptides encoded thereby, and methods of using the same |
-
2004
- 2004-09-20 JP JP2006526617A patent/JP2007521015A/ja active Pending
- 2004-09-20 BR BRPI0414446-5A patent/BRPI0414446A/pt not_active IP Right Cessation
- 2004-09-20 WO PCT/EP2004/010780 patent/WO2005026735A2/en not_active Ceased
- 2004-09-20 CA CA002539490A patent/CA2539490A1/en not_active Abandoned
- 2004-09-20 US US10/571,167 patent/US20090252721A1/en not_active Abandoned
- 2004-09-20 EP EP04765615A patent/EP1673470A2/en not_active Ceased
- 2004-09-20 SG SG200806620-1A patent/SG146622A1/en unknown
- 2004-09-20 CN CNA200480034085XA patent/CN1902326A/zh active Pending
- 2004-09-20 EP EP08163922A patent/EP2050827A3/en not_active Withdrawn
- 2004-09-20 AU AU2004272747A patent/AU2004272747A1/en not_active Abandoned
-
2006
- 2006-03-01 IL IL174047A patent/IL174047A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20090252721A1 (en) | 2009-10-08 |
| CN1902326A (zh) | 2007-01-24 |
| WO2005026735A2 (en) | 2005-03-24 |
| JP2007521015A (ja) | 2007-08-02 |
| CA2539490A1 (en) | 2005-03-24 |
| IL174047A0 (en) | 2006-08-01 |
| BRPI0414446A (pt) | 2006-11-14 |
| WO2005026735A3 (en) | 2005-11-03 |
| EP1673470A2 (en) | 2006-06-28 |
| EP2050827A3 (en) | 2009-09-02 |
| EP2050827A2 (en) | 2009-04-22 |
| AU2004272747A1 (en) | 2005-03-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG146622A1 (en) | Differentially expressed tumour-specific polypeptides for use in the diagnosis and treatment of cancer | |
| Chae et al. | The B30. 2 domain of pyrin, the familial Mediterranean fever protein, interacts directly with caspase-1 to modulate IL-1β production | |
| Jiang et al. | Formation of tissue factor–factor VIIa–factor Xa complex promotes cellular signaling and migration of human breast cancer cells | |
| Rygiel et al. | CD200R signaling in tumor tolerance and inflammation: A tricky balance | |
| Schaer et al. | Molecular cloning and characterization of the mouse CD163 homologue, a highly glucocorticoid-inducible member of the scavenger receptor cysteine-rich family. | |
| Lin et al. | Wnt signaling activation and WIF-1 silencing in nasopharyngeal cancer cell lines | |
| Izumoto et al. | Gene expression of neural cell adhesion molecule L1 in malignant gliomas and biological significance of L1 in glioma invasion | |
| Xiang et al. | Isolation of complementary DNA encoding K-cadherin, a novel rat cadherin preferentially expressed in fetal kidney and kidney carcinoma | |
| WO2005100998A3 (en) | Membrane markers for use in cancer diagnosis and therapy | |
| EA200600055A1 (ru) | Агонисты рецептора меланокортина 4 (мк4 ) и их применение | |
| BR0306973A (pt) | Anticorpos anti-igf-ir e respectivas aplicações | |
| EP0813545A4 (en) | Nucleotide and protein sequences of vertebrate serrate genes and methods based thereon | |
| EP3149478B1 (en) | Senescent cell biomarkers | |
| CY1106991T1 (el) | Αντιπολλαπλασιαστικη δραση ολιγονουκλεοτιδιων πλουσιων σε g και μεθοδος χρησιμοποιησης αυτων για την προσδεση σε νουκλεολινη | |
| Machida et al. | Increased expression of proapoptotic BMCC1, a novel gene with the BNIP2 and Cdc42GAP homology (BCH) domain, is associated with favorable prognosis in human neuroblastomas | |
| Imai et al. | Evidence for tight coupling of gonadotropin-releasing hormone receptor to stimulated Fas ligand expression in reproductive tract tumors: possible mechanism for hormonal control of apoptotic cell death | |
| Southby et al. | Cell-specific and regulator-induced promoter usage and messenger ribonucleic acid splicing for parathyroid hormone-related protein | |
| WO2002032953A3 (en) | Pregnancy-associated plasma protein-a2 (papp-a2) | |
| Rybczynska et al. | MDR1 causes resistance to the antitumour drug miltefosine | |
| Tadei et al. | Expression of the Annexin A1 and its correlation with matrix metalloproteinases and the receptor for formylated peptide-2 in diffuse astrocytic tumors | |
| EP1536006A4 (en) | CANCER-ANIMALS AND THEIR USE | |
| WO2003046147A3 (en) | Novel human g-protein coupled receptor, hgprbmy31, and variants and methods of use thereof | |
| WO2007036945A2 (en) | Hepatocyte growth factor receptor splice variants and methods of using same | |
| Vannini et al. | Short interfering RNA directed against the SLUG gene increases cell death induction in human melanoma cell lines exposed to cisplatin and fotemustine | |
| EP1887082A3 (en) | TADG-15: An extracellular serine protease overexpressed in carcinomas |